• Home
  •  / Dottikon Exclusive Synthesis

Dottikon Exclusive Synthesis

OverviewSuggest Edit

Dottikon Exclusive Synthesis (also known as Dottikon Es Holding) is a company that manufactures active pharmaceutical ingredients (APIs), intermediates, and performance chemicals. It also provides chemical custom manufacturing services, including route-finding, process development, small-scale and pilot production, manufacturing, qualification, and validation. The company serves the chemical and pharmaceutical industries.

TypePublic
Founded1913
HQDottikon, CHMap
Websitedottikon.com

Recent NewsAll News

Latest Updates

Employees (est.) (Dec 2020)630(+4%)
Revenue (FY, 2020)CHF174.8 M(+19%)
Share Price (Dec 2020)€48
Cybersecurity ratingDMore

Key People/Management at Dottikon Exclusive Synthesis

Markus Blocher

Markus Blocher

Chairman, CEO
Alfred Scheidegger

Alfred Scheidegger

Deputy Chairman
Marlene Born

Marlene Born

CFO
Stephan Kirschbaum

Stephan Kirschbaum

Head of Business Development
Karin Krause

Karin Krause

Head of Human Resources
Urs Brändli

Urs Brändli

Head of Processes & Technologies
Show more

Dottikon Exclusive Synthesis Office Locations

Dottikon Exclusive Synthesis has offices in Dottikon and Chicago
Dottikon, CH (HQ)
17 Hembrunnstrasse
Chicago, IL, US
3559 N Cumberland Ave #106
Show all (2)

Dottikon Exclusive Synthesis Financials and Metrics

Dottikon Exclusive Synthesis Revenue

Embed Graph
View revenue for all periods
Dottikon Exclusive Synthesis's revenue was reported to be CHF174.77 m in FY, 2020 which is a 18.3% increase from the previous period.
CHF

Revenue (H1, 2021)

91.8m

Gross profit (H1, 2021)

(25.5b)

Gross profit margin (H1, 2021), %

(27807.4%)

Net income (H1, 2021)

21.1m

EBITDA (H1, 2021)

33.9m

EBIT (H1, 2021)

24.6m

Market capitalization (16-Dec-2020)

5.7b

Closing stock price (16-Dec-2020)

48.0

Cash (30-Sept-2020)

66.6m
Dottikon Exclusive Synthesis's current market capitalization is €5.7 b.
Annual
CHFFY, 2018FY, 2019FY, 2020

Revenue

158.2m147.7m174.8m

Revenue growth, %

(7%)18%

Cost of goods sold

35.9m39.5m44.8m

Gross profit

122.4m108.2m129.9m
Half Year
CHFH1, 2018H1, 2019H1, 2020H1, 2021

Revenue

70.1m56.6m77.9m91.8m

Cost of goods sold

15.9m17.4m23.2m25.6b

Gross profit

54.2m39.2m54.8m(25.5b)

Gross profit Margin, %

77%69%70%(27807%)
show all
Annual
CHFFY, 2018FY, 2019FY, 2020

Cash

46.7m43.8m42.8m

Accounts Receivable

53.9m41.2m35.1m

Prepaid Expenses

1.2m1.4m

Inventories

52.1m67.1m78.7m
Half Year
CHFH1, 2018H1, 2019H1, 2020H1, 2021

Cash

65.6m56.9m38.7m66.6m

Accounts Receivable

24.2m24.0m41.7m23.3m

Prepaid Expenses

1.7m1.9m1.8m

Inventories

51.7m63.4m76.6m89.9m
show all
Annual
CHFFY, 2018FY, 2019FY, 2020

Net Income

25.9m16.3m33.2m

Depreciation and Amortization

16.3m20.1m18.9m

Inventories

(6.7m)(14.9m)(11.6m)

Accounts Payable

1.7m2.6m(1.6m)
Half Year
CHFH1, 2018H1, 2019H1, 2020H1, 2021

Net Income

9.6m2.0m15.4m21.1m

Depreciation and Amortization

8.6m7.4m9.2m9.3m

Inventories

(6.3m)(11.2m)(9.5m)(11.3m)

Accounts Payable

2.6m959.0k(1.0m)1.8m
show all
CHFH1, 2018

Financial Leverage

1.2 x
Show all financial metrics

Dottikon Exclusive Synthesis Operating Metrics

Nov, 2020

Manufacturing Space, sq. m.

600 k

Products and Services

9
Show all operating metrics

Dottikon Exclusive Synthesis Revenue Breakdown

Embed Graph

Dottikon Exclusive Synthesis revenue breakdown by business segment: 39.8% from Active Pharmaceutical Ingredients, 54.2% from Pharma Products, 5.4% from Performance Chemicals and 0.6% from Other

Dottikon Exclusive Synthesis Cybersecurity Score

Cybersecurity ratingPremium dataset

D

69/100

Learn more about our premium products
SecurityScorecard logo

Dottikon Exclusive Synthesis Online and Social Media Presence

Dottikon Exclusive Synthesis's Trends

Embed Graph

Dottikon Exclusive Synthesis News and Updates

October 22, 2020

Considerably Lower Net Sales and Net Income

DOTTIKON ES Group, positioned as strategic development and manufacturing partner and specialized in the area of hazardous reactions and the exclusive synthesis of active pharmaceutical ingredients (API) and fine chemicals, closed its first business half-year 2018/19 on September 30, 2018. The corre…
October 20, 2020

DOTTIKON ES Proposes Share Split and Authorized Capital Increase for Growth

DOTTIKON ES Group, positioned as strategic development and manufacturing partner and specialized in the area of hazardous reactions and the exclusive synthesis of active pharmaceutical ingredients (API) and fine chemicals, will propose a share split and an authorized capital increase to support its…
July 03, 2020

DOTTIKON ES' Shareholders Approve all Proposals of the Board of Directors

Due to the coronavirus pandemic, DOTTIKON ES HOLDING AG's 15th Annual General Meeting took place without the physical presence of the shareholders, who sent in their voting instructions electronically or via mail and approved all proposals of the Board of Directors. The 486 shareholders who partici…
May 29, 2020

Annual Report 2019/20: Higher Sales and Net Income – Investments in Further Growth

SIX-listed DOTTIKON ES HOLDING AG closed its business year 2019/20 on March 31, 2020. ƒ Net sales of CHF 174.8 million, up 18.3 percent compared to the previous year ƒ EBITDA of CHF 55.4 million, up 39.0 percent compared to the previous year ƒ EBITDA margin of 31.7 percent (previous year: 27.0 p…
February 07, 2020

DOTTIKON ES Expects Growth Momentum and Appoints Dr. Bernhard Urwyler as Advisor

DOTTIKON ES Group, positioned as strategic development and manufacturing partner and specialized in the area of hazardous reactions and the exclusive synthesis of active pharmaceutical ingredients (API) and fine chemicals, appoints Dr. Bernhard Urwyler as advisory counselor.
January 02, 2020

Handover of Production Senior Management Position

DOTTIKON ES Group, positioned as strategic development and manufacturing partner and specialized in the area of hazardous reactions and the exclusive synthesis of active pharmaceutical ingredients (API) and fine chemicals, appoints Dr. Robert Dahinden as member of the Senior Management and Head of …
Show more

 Dottikon Exclusive Synthesis Frequently Asked Questions

  • When was Dottikon Exclusive Synthesis founded?

    Dottikon Exclusive Synthesis was founded in 1913.

  • Who are Dottikon Exclusive Synthesis key executives?

    Dottikon Exclusive Synthesis's key executives are Markus Blocher, Alfred Scheidegger and Marlene Born.

  • How many employees does Dottikon Exclusive Synthesis have?

    Dottikon Exclusive Synthesis has 630 employees.

  • What is Dottikon Exclusive Synthesis revenue?

    Latest Dottikon Exclusive Synthesis annual revenue is CHF174.8 m.

  • What is Dottikon Exclusive Synthesis revenue per employee?

    Latest Dottikon Exclusive Synthesis revenue per employee is CHF277.4 k.

  • Who are Dottikon Exclusive Synthesis competitors?

    Competitors of Dottikon Exclusive Synthesis include CPH Chemie + Papier Holding, SEQENS and Zambon.

  • Where is Dottikon Exclusive Synthesis headquarters?

    Dottikon Exclusive Synthesis headquarters is located at 17 Hembrunnstrasse, Dottikon.

  • Where are Dottikon Exclusive Synthesis offices?

    Dottikon Exclusive Synthesis has offices in Dottikon and Chicago.

  • How many offices does Dottikon Exclusive Synthesis have?

    Dottikon Exclusive Synthesis has 2 offices.